Long-Acting Aripiprazole Injection: Safety and Drug Levels in Schizophrenia
About this title
Read the official source — NCT01870999This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.
Understand this study
What did researchers investigate?
This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Cerritos and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT01870999
- Official title
Show the full official title
An Open-label Parallel Arm Multiple Dose Tolerability, Pharmacokinetics and Safety Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot Formulation Once Every Four Weeks
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Cerritos · Garden Grove · Glendale
4 more locations
- Paramount
- St Louis
- Willingboro
- Austin
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of aripiprazole IM depot for people with schizophrenia.
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including aripiprazole IM depot and aripiprazole tablets.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
